[Federal Register Volume 65, Number 248 (Tuesday, December 26, 2000)]
[Notices]
[Page 81533]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-32816]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Hydroxylamine 
Compositions for the Prevention or Retardation of Cataracts

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c))1) and 37 CFR 
404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, in contemplating the grant of 
an exclusive license worldwide to practice the invention embodied in: 
U.S. Patent Number 6,001,853 issued December 14, 1999 entitled, 
``Hydroxylamine Compositions for the Prevention or Retardation of 
Cataracts'', to SL Pharmaceuticals, having a place of business in 
Kennett Square, PA 19348. The contemplated exclusive license may be 
limited to use for human therapeutics and diagnostics. The United 
States of America is the assignee of the patent rights in this 
invention.

DATES: Only written comments and/or application for a license which is 
received by the NIH Office of Technology Transfer on or before February 
26, 2001, will be considered.

ADDRESSES: Request for a copy of the patent, inquiries, comments and 
other materials relating to the contemplated license should be directed 
to: Marlene Shinn, Technology Licensing Specialist, Office of 
Technology Transfer, National Institutes of Health, 6011 Executive 
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: 301-496-7056 
ext. 285; Facsimile: 301-402-0220; E-mail: [email protected].

SUPPLEMENTARY INFORMATION: Cataracts are believed to be a disease of 
multifactorial origin involving many of the same processes that 
characterize the process of aging in other issues. This invention 
relates generally to a pharmaceutical composition and treatment to 
inhibit the development of cataracts in the crystalline lens of the eye 
by administering a hydroxylamine to a patient at risk of developing a 
cataract. This technology is an improvement over what is presently 
known, in that it allows for a clinically useful non-surgical treatment 
that retards the development of age-related cataracts.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 60 days 
from the date of this published Notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: December 15, 2000.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 00-32816 Filed 12-22-00; 8:45 am]
BILLING CODE 4140-01-M